Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10293001" target="_blank" >RIV/00064203:_____/14:10293001 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.jacc.2014.02.549" target="_blank" >http://dx.doi.org/10.1016/j.jacc.2014.02.549</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jacc.2014.02.549" target="_blank" >10.1016/j.jacc.2014.02.549</a>

Result language
angličtina
Original language name
Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
Original language description
Objectives This study sought to characterize major bleeding on the basis of the components of the major bleeding definition, to explore major bleeding by location, to define 30-day mortality after a major bleeding event, and to identify factors associated with major bleeding. Background Apixaban was shown to reduce the risk of major hemorrhage among patients with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. MethodsAll patients who received at least 1 dose of a study drug were included. Major bleeding was defined according to the criteria of the International Society on Thrombosis and Haemostasis. Factors associated with major hemorrhage were identified using a multivariable Cox model. Results The on-treatment safety population included 18,140 patients. The rate of major hemorrhage among patients in the apixaban group was 2.13% per year compared with 3.09% per year in the warfarin group (hazard rat
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)